Stories

insights

Tales from the Trenches with Debra Geihsler, CEO of Activate Healthcare

August 8, 2019

For Debra Geihsler, the answer to reducing healthcare costs and improving wellness outcomes is a simple one: Figure out how to keep patients out of the hospital in the first place.

Debra spent decades leading healthcare organizations, including eight years as CEO of the 1200-provider combined Harvard Vanguard Medical Group and Atrius Health System in Boston, and two years at Advocate Medical G…

Read more

insights

Partner Insights: IP advice from Polsinelli’s Morgan Kirley

July 24, 2019

Does intellectual property affect your startup?

According to Morgan Kirley — an intellectual property and privacy lawyer at Polsinelli and MATTER mentor — intellectual property law affects some component of every company.

We sat down with Morgan to discuss the basics that every startup needs to know.

Interested in hearing from more Polsinelli lawyers? Check back next month to hear from Lis…

Read more

insights

Delivering better outcomes for America's seniors

July 12, 2019

A discussion with Welltower CEO Tom DeRosa

The aging U.S. population is growing at its fastest rate in history. This large-scale demographic change brings with it new challenges — challenges that need innovative solutions.

In June, Tom DeRosa, CEO of Welltower and a MATTER board member, joined us at MATTER to share advice on how healthcare companies can deliver better care to the aging popula…

Read more

insights

How can tech make the end of life more human?

July 10, 2019

A discussion with Dr. Shoshana Ungerleider

Last month, we hosted a screening of End Game, the Netflix documentary The New York Times calls a provocative and intimate look at how doctors, nurses and patients cope with death.

What’s it going to take for us to see talking about care at the end of life as a normal wellness practice? -@ShoshUMD #RoadtoEndWell pic.twitter.com/QpTcwZiXI0— MATT…

Read more

insights

Building a mission-driven company: A fireside chat with Forty Seven, Inc.’s Dr. Mark Chao and Mark McCamish

June 26, 2019

A race is underway to develop the next major checkpoint inhibitor that harnesses the innate immune system.

At the forefront is Forty Seven, Inc., a clinical stage immuno-oncology company founded in 2015 that developed out of a lab at Stanford University. The company focuses on targeting the CD47 pathway as a way to engage macrophages — the body’s first responders — in fighting tumors.

Last mo…

Read more